Form 4: PLAYSTUDIOS General Counsel Sells Over 40,000 Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
Joel Agena, General Counsel of PLAYSTUDIOS, Inc., sold a total of 40,490 shares of Class A Common Stock on July 1 and July 2, 2025, under a pre-established Rule 10b5-1 trading plan.
Summary
- Joel Agena, General Counsel of PLAYSTUDIOS, Inc. (MYPS), executed sales of Class A Common Stock.
- On July 1, 2025, 20,490 shares were sold at a weighted average price of $1.33 per share, with prices ranging from $1.30 to $1.35.
- On July 2, 2025, an additional 20,000 shares were sold at a weighted average price of $1.35 per share, with prices ranging from $1.33 to $1.38.
- These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2025, and previously disclosed in the company's Form 10-Q filed on May 9, 2025.
- Following these sales, Joel Agena directly beneficially owns 75,301 shares of Class A Common Stock.
- Joel Agena also holds various derivative securities, including 291,668 Restricted Stock Units, 125,000 Performance Stock Units, 233,043 Stock Options, and 28,040 Earnout Shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral to slightly negative. While the sales are pre-planned via a 10b5-1 plan, which mitigates negative perception, the sale of a significant number of shares by a key executive at relatively low prices (below $1.40) could be viewed with caution by investors. However, the executive retains substantial unvested equity, indicating continued alignment.
Positives
- Continued significant holdings of derivative securities (291,668 RSUs, 125,000 PSUs, 233,043 Stock Options, 28,040 Earnout Shares) indicate ongoing alignment with shareholder interests.
- The sales were conducted under a pre-established Rule 10b5-1 trading plan, which suggests a planned, rather than reactive, disposition of shares.
Negatives
- The sale of 40,490 shares by a General Counsel could be perceived negatively by some investors, especially given the relatively low sale prices of $1.33 and $1.35.
- The sale price range ($1.30-$1.38) is significantly below the earnout share price targets ($12.50 and $15.00), highlighting a current valuation gap.
Risks
- Performance Stock Units vesting is contingent upon the achievement of certain pre-established performance metrics for the fiscal year ending December 31, 2025, which may not be met.
- Earnout shares are contingent on the Class A Common Stock closing price exceeding $12.50 and $15.00 per share for specific trading periods, which may not occur by the June 21, 2026, expiration.
- Stock options have exercise prices ($1.01, $1.44, $0.9) that are close to or above the current sale prices, indicating limited immediate profitability for some tranches.
Future Outlook
The vesting of Performance Stock Units is contingent on the achievement of pre-established performance metrics for the fiscal year ending December 31, 2025. Additionally, earnout shares are contingent on the Class A Common Stock reaching specific price targets of $12.50 and $15.00 per share by June 21, 2026.
Management Comments
- The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the reported ranges.
Industry Context
This Form 4 filing reflects a routine insider transaction under a pre-arranged trading plan, common among executives for personal financial planning. It does not inherently indicate a shift in broader industry trends for the gaming or entertainment sector, but rather an individual executive's portfolio management.
Stakeholder Impact
- Shareholders: The sale of shares by a General Counsel, even under a 10b5-1 plan, might lead to questions about management's confidence in the near-term stock price, especially given the low sale prices relative to earnout targets. However, the executive's continued significant equity holdings (RSUs, PSUs, options) suggest ongoing alignment with long-term shareholder value.
Next Steps
- Vesting of 125,000 Restricted Stock Units on May 15, 2025.
- Vesting of 41,667 Restricted Stock Units on May 15, 2025.
- Determination of Performance Stock Units vesting based on fiscal year 2025 performance metrics (ending December 31, 2025).
- Vesting of 41,667 Restricted Stock Units on January 15, 2026.
- Vesting of 83,334 Restricted Stock Units on May 15, 2026.
- Potential vesting of Earnout Shares if price targets ($12.50, $15.00) are met by June 21, 2026.
- Expiration of Stock Options with an exercise price of $0.9 on September 1, 2025.
Key Dates
| Date | Description |
|---|---|
| 09/01/2018 | Grant date for Stock Options with an exercise price of $0.9, expiring 09/01/2025. |
| 05/01/2020 | Grant date for Stock Options with an exercise price of $1.01, expiring 05/01/2027. |
| 02/01/2021 | Date of the Agreement and Plan of Merger for the business combination related to earnout shares. |
| 01/01/2023 | Grant date for Stock Options with an exercise price of $1.44, expiring 01/01/2029. |
| 03/11/2024 | Grant date for 358,335 unvested Restricted Stock Units. |
| 05/15/2024 | Vesting date for 66,667 Restricted Stock Units from the March 11, 2024 grant. |
| 03/07/2025 | Grant date for 166,667 unvested Restricted Stock Units. |
| 03/12/2025 | Adoption date of the Rule 10b5-1 trading plan by the reporting person. |
| 05/09/2025 | Filing date of the Issuer's Quarterly Report on Form 10-Q, where the 10b5-1 plan was previously disclosed. |
| 05/15/2025 | Vesting date for 125,000 Restricted Stock Units from the March 11, 2024 grant and 41,667 Restricted Stock Units from the March 7, 2025 grant. |
| 07/01/2025 | Transaction date for the sale of 20,490 shares of Class A Common Stock. |
| 07/02/2025 | Transaction date for the sale of 20,000 shares of Class A Common Stock. |
| 07/03/2025 | Signature date of the Form 4 filing. |
| 09/01/2025 | Expiration date for Stock Options with an exercise price of $0.9. |
| 12/31/2025 | End of fiscal year for which Performance Stock Units achievement will be determined. |
| 01/15/2026 | Vesting date for 41,667 Restricted Stock Units from the March 7, 2025 grant. |
| 05/15/2026 | Vesting date for 83,334 Restricted Stock Units from the March 11, 2024 grant. |
| 06/21/2026 | Expiration date for Earnout Shares. |
| 01/15/2027 | Vesting date for 41,667 Restricted Stock Units from the March 7, 2025 grant. |
| 05/01/2027 | Expiration date for Stock Options with an exercise price of $1.01. |
| 05/15/2027 | Vesting date for 83,334 Restricted Stock Units from the March 11, 2024 grant. |
| 01/15/2028 | Vesting date for 41,666 Restricted Stock Units from the March 7, 2025 grant. |
| 01/01/2029 | Expiration date for Stock Options with an exercise price of $1.44. |
Recommendation
holdKeywords
PLAYSTUDIOS, MYPS, SEC Form 4, Insider Trading, Stock Sale, Joel Agena, General Counsel, Rule 10b5-1 Plan, Restricted Stock Units, Performance Stock Units, Stock Options, Earnout Shares, Corporate Governance, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.